[Antibody therapy in hematology and oncology--2].
Kneba
Michael
M
II Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany. sekretariat@med2.uni-kiel.de
Schrader
Carsten
C
Köhne
Henning
H
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000276:immunology; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000939:Epitopes